China NMPA Product Recall - Drug-eluting coronary stent systems and rapid exchange coronary stent systems

Medtronic Inc., supported by its Chinese entity Medtronic (Shanghai) Management Co., Ltd., initiated a voluntary recall of specific drug-eluting coronary stent systems and fast-exchange coronary stent systems, as documented by the National Medical Products Administration (NMPA) on July 20, 2016. The recall was prompted by the discovery of unauthorized tampering and the use of counterfeit outer packaging product labels by an unaffiliated third-party distributor in Europe. Investigations revealed instances where products were incorrectly labeled, for example, drug-eluting stents potentially packaged with fast-exchange stent labels. While the internal product labels remained correct, and Medtronic confirmed that the quality and safety of the devices were not compromised, the company decided to recall all affected products shipped from its European distribution centers after March 29, 2016. The recall primarily impacted regions like the Americas and Europe. Significantly, no affected products were sold or imported into China, rendering direct corrective actions by Medtronic within China unnecessary. The NMPA, however, requested provincial and autonomous region drug regulatory authorities to strengthen their supervision and management of similar products.